metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) | |
squamous - mNSCLC - L1 - all population | |
ipilimumab plus SoC | CA184-104 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -